Biofrontera Inc (BFRI) - Net Assets
Based on the latest financial reports, Biofrontera Inc (BFRI) has net assets worth $6.07 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($24.79 Million) and total liabilities ($18.72 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore BFRI asset base for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.07 Million |
| % of Total Assets | 24.49% |
| Annual Growth Rate | N/A |
| 5-Year Change | -7.57% |
| 10-Year Change | N/A |
| Growth Volatility | 81.62 |
Biofrontera Inc - Net Assets Trend (2019–2025)
This chart illustrates how Biofrontera Inc's net assets have evolved over time, based on quarterly financial data. Check Biofrontera Inc (BFRI) tangible net worth to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Biofrontera Inc (2019–2025)
The table below shows the annual net assets of Biofrontera Inc from 2019 to 2025. For live valuation and market cap data, see how much is Biofrontera Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $10.48 Million | +136.41% |
| 2024-12-31 | $4.43 Million | -7.51% |
| 2023-12-31 | $4.79 Million | -79.93% |
| 2022-12-31 | $23.88 Million | +110.60% |
| 2021-12-31 | $11.34 Million | +94.54% |
| 2020-12-31 | $5.83 Million | +119.31% |
| 2019-12-31 | $-30.18 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biofrontera Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9776600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $12.00K | 0.11% |
| Other Components | $138.41 Million | 1320.73% |
| Total Equity | $10.48 Million | 100.00% |
Biofrontera Inc Competitors by Market Cap
The table below lists competitors of Biofrontera Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MOGU Inc
NYSE:MOGU
|
$14.47 Million |
|
Soder Sportfiske AB
ST:SODER
|
$14.47 Million |
|
Grupo Televisa SAB DRC
BA:TV
|
$14.47 Million |
|
Klassik Radio AG
XETRA:KA8
|
$14.47 Million |
|
Vertice Bhd
KLSE:7240
|
$14.45 Million |
|
SciDev Limited
F:INFA
|
$14.45 Million |
|
Mixed Martial Arts Group Limited
NYSE MKT:MMA
|
$14.43 Million |
|
Rougier S.A.
PA:ALRGR
|
$14.43 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biofrontera Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,433,000 to 10,480,000, a change of 6,047,000 (136.4%).
- Net loss of 10,536,000 reduced equity.
- New share issuances of 10,850,000 increased equity.
- Other factors increased equity by 5,733,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-10.54 Million | -100.53% |
| Share Issuances | $10.85 Million | +103.53% |
| Other Changes | $5.73 Million | +54.7% |
| Total Change | $- | 136.41% |
Book Value vs Market Value Analysis
This analysis compares Biofrontera Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.30x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-49.72 | $1.17 | x |
| 2020-12-31 | $10.05 | $1.17 | x |
| 2021-12-31 | $13.26 | $1.17 | x |
| 2022-12-31 | $22.59 | $1.17 | x |
| 2023-12-31 | $3.10 | $1.17 | x |
| 2024-12-31 | $0.80 | $1.17 | x |
| 2025-12-31 | $0.90 | $1.17 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biofrontera Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -100.53%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -25.26%
- • Asset Turnover: 1.46x
- • Equity Multiplier: 2.73x
- Recent ROE (-100.53%) is above the historical average (-206.43%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -41.95% | 0.91x | 0.00x | $-7.96 Million |
| 2020 | -188.52% | -58.29% | 0.78x | 4.14x | $-11.57 Million |
| 2021 | -332.62% | -156.49% | 0.45x | 4.69x | $-38.85 Million |
| 2022 | -2.68% | -2.23% | 0.56x | 2.13x | $-3.03 Million |
| 2023 | -420.01% | -59.09% | 1.22x | 5.83x | $-20.61 Million |
| 2024 | -400.61% | -47.61% | 1.69x | 4.99x | $-18.20 Million |
| 2025 | -100.53% | -25.26% | 1.46x | 2.73x | $-11.58 Million |
Industry Comparison
This section compares Biofrontera Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $195,817,616
- Average return on equity (ROE) among peers: -66.14%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biofrontera Inc (BFRI) | $6.07 Million | 0.00% | 3.08x | $14.47 Million |
| Aurora Cannabis Inc (ACB) | $1.68 Million | -10.54% | 0.00x | $164.96 Million |
| Akanda Corp (AKAN) | $-5.03 Million | 0.00% | 0.00x | $2.84 Million |
| Akebia Ther (AKBA) | $635.93 Million | -27.03% | 0.57x | $340.21 Million |
| Alkermes Plc (ALKS) | $58.35 Million | -183.19% | 3.99x | $7.49 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-66.72 Million | 0.00% | 0.00x | $1.64 Billion |
| Amphastar P (AMPH) | $251.54 Million | 4.72% | 0.35x | $854.96 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $61.30 Million | -137.01% | 55.65x | $5.21 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $896.36 Million | -18.93% | 3.86x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $108.93 Million | 10.79% | 0.30x | $196.52 Million |
| ANI Pharmaceuticals Inc (ANIP) | $15.83 Million | -300.23% | 1.30x | $1.78 Billion |
About Biofrontera Inc
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquarte… Read more